Exabis Library
Welcome to the e-CCO Library!
P722: Trough levels, drug switching and antidrug antibody loss: Analysis of real-life infliximab and adalimumab data in IBD
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P723 Therapeutic thresholds for golimumab serum concentrations during induction and maintenance: Results from the GO-LEVEL study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P723: Comparison of the Persistence Rates of Biologic Agents in Paediatric Crohn's Disease Patients (Japanese Paediatric IBD Registry Study)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P723: Effectiveness and persistence of vedolizumab in patients with Inflammatory bowel Disease: Results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P723: Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with iron isomaltoside or ferric carboxymaltose: results of a prospective cluster randomised cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P723: SexIDI study – sexual satisfaction in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P724 Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P724: Appendectomy is not a treatment option for ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P724: Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease: Results from a prospective study (SECURE)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P724: Upadacitinib is Effective and Safe in Tofacitinib-Experienced Patients with Ulcerative Colitis: A Prospective Real-World Experience
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P724: Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P725 Trends in biologic use prior to resective surgery for inflammatory bowel disease: A Canadian population-based study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P725: A prospective study of planned switch from Infliximab originator remicade to biosimilar inflectra: a multi-centre Irish experience
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P725: Ileal pouch excision: A contemporary observational cohort
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P725: Patients with Immune Mediated Inflammatory Diseases are insufficiently protected against vaccine-preventable influenza and pneumococcal infections due to low vaccination rates
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P725: The impact of an integrated model of care for patients with inflammatory bowel disease in Canada
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P726 Effectiveness of vedolizumab therapy in a real-world setting in Germany: First results of the VEDOibd study comparing vedolizumab to the use of other biologics
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P726: Fecal calprotectin and quality of life questionnaires are responsive to change in pouch disease activity following antibiotic therapy—results from a prospective clinical trial
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P726: High mortality risk after first hospital admission for inflammatory bowel disease: a nationwide registry linkage study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P726: Metalloproteinase 3: A new marker for assessing loss of response to infliximab in IBD
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM